Target/Host (Institution) | Ligand | Target/Host Links | Ligand Links | Trg + Lig Links | Ki nM | ΔG° kJ/mole | IC50 nM | Kd nM | EC50/IC50 nM | koff s-1 | kon M-1s-1 | pH | Temp °C |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Hexokinase-4 (Homo sapiens (Human)) | BDBM439303![]() (US10633348, Compound (A-17)) | PDB MMDB NCI pathway Reactome pathway KEGG UniProtKB/SwissProt B.MOAD DrugBank antibodypedia GoogleScholar AffyNet ![]() | PC cid PC sid UniChem | US Patent | n/a | n/a | 17 | n/a | n/a | n/a | n/a | n/a | n/a |
Dana-Farber Cancer Institute, Inc. US Patent | Assay Description The in vitro activity of the compounds described herein in inhibiting TAK1, HCK and other kinases were obtained using an Invitrogen Select Screening ... | US Patent US10633348 (2020) BindingDB Entry DOI: 10.7270/Q22Z18JR | |||||||||||
More data for this Ligand-Target Pair | |||||||||||||
Tyrosine-protein kinase HCK (Homo sapiens (Human)) | BDBM439316![]() (US10633348, Compound (A-12)) | PDB MMDB Reactome pathway KEGG UniProtKB/SwissProt B.MOAD DrugBank antibodypedia GoogleScholar AffyNet ![]() | PC cid PC sid UniChem | US Patent | n/a | n/a | 18 | n/a | n/a | n/a | n/a | n/a | n/a |
Dana-Farber Cancer Institute, Inc. US Patent | Assay Description The in vitro activity of the compounds described herein in inhibiting TAK1, HCK and other kinases were obtained using an Invitrogen Select Screening ... | US Patent US10633348 (2020) BindingDB Entry DOI: 10.7270/Q22Z18JR | |||||||||||
More data for this Ligand-Target Pair | |||||||||||||
Tyrosine-protein kinase HCK (Homo sapiens (Human)) | BDBM439318![]() (US10633348, Compound (A-14)) | PDB MMDB Reactome pathway KEGG UniProtKB/SwissProt B.MOAD DrugBank antibodypedia GoogleScholar AffyNet ![]() | PC cid PC sid UniChem | US Patent | n/a | n/a | 27.4 | n/a | n/a | n/a | n/a | n/a | n/a |
Dana-Farber Cancer Institute, Inc. US Patent | Assay Description The in vitro activity of the compounds described herein in inhibiting TAK1, HCK and other kinases were obtained using an Invitrogen Select Screening ... | US Patent US10633348 (2020) BindingDB Entry DOI: 10.7270/Q22Z18JR | |||||||||||
More data for this Ligand-Target Pair | |||||||||||||
Tyrosine-protein kinase HCK (Homo sapiens (Human)) | BDBM439303![]() (US10633348, Compound (A-17)) | PDB MMDB Reactome pathway KEGG UniProtKB/SwissProt B.MOAD DrugBank antibodypedia GoogleScholar AffyNet ![]() | PC cid PC sid UniChem | US Patent | n/a | n/a | 28 | n/a | n/a | n/a | n/a | n/a | n/a |
Dana-Farber Cancer Institute, Inc. US Patent | Assay Description The in vitro activity of the compounds described herein in inhibiting TAK1, HCK and other kinases were obtained using an Invitrogen Select Screening ... | US Patent US10633348 (2020) BindingDB Entry DOI: 10.7270/Q22Z18JR | |||||||||||
More data for this Ligand-Target Pair | |||||||||||||
Hexokinase-4 (Homo sapiens (Human)) | BDBM439304![]() (US10633348, Compound (A-2)) | PDB MMDB NCI pathway Reactome pathway KEGG UniProtKB/SwissProt B.MOAD DrugBank antibodypedia GoogleScholar AffyNet ![]() | PC cid PC sid UniChem | US Patent | n/a | n/a | 28 | n/a | n/a | n/a | n/a | n/a | n/a |
Dana-Farber Cancer Institute, Inc. US Patent | Assay Description The in vitro activity of the compounds described herein in inhibiting TAK1, HCK and other kinases were obtained using an Invitrogen Select Screening ... | US Patent US10633348 (2020) BindingDB Entry DOI: 10.7270/Q22Z18JR | |||||||||||
More data for this Ligand-Target Pair | |||||||||||||
Hexokinase-4 (Homo sapiens (Human)) | BDBM438001![]() (US10633348, Compound (A-1) | US10633348, Compound ...) | PDB MMDB NCI pathway Reactome pathway KEGG UniProtKB/SwissProt B.MOAD DrugBank antibodypedia GoogleScholar AffyNet ![]() | PC cid PC sid UniChem | US Patent | n/a | n/a | 31 | n/a | n/a | n/a | n/a | n/a | n/a |
Dana-Farber Cancer Institute, Inc. US Patent | Assay Description The in vitro activity of the compounds described herein in inhibiting TAK1, HCK and other kinases were obtained using an Invitrogen Select Screening ... | US Patent US10633348 (2020) BindingDB Entry DOI: 10.7270/Q22Z18JR | |||||||||||
More data for this Ligand-Target Pair | |||||||||||||
Tyrosine-protein kinase HCK (Homo sapiens (Human)) | BDBM439309![]() (US10633348, Compound (A-7)) | PDB MMDB Reactome pathway KEGG UniProtKB/SwissProt B.MOAD DrugBank antibodypedia GoogleScholar AffyNet ![]() | PC cid PC sid UniChem | US Patent | n/a | n/a | 33.8 | n/a | n/a | n/a | n/a | n/a | n/a |
Dana-Farber Cancer Institute, Inc. US Patent | Assay Description The in vitro activity of the compounds described herein in inhibiting TAK1, HCK and other kinases were obtained using an Invitrogen Select Screening ... | US Patent US10633348 (2020) BindingDB Entry DOI: 10.7270/Q22Z18JR | |||||||||||
More data for this Ligand-Target Pair | |||||||||||||
Tyrosine-protein kinase HCK (Homo sapiens (Human)) | BDBM439308![]() (US10633348, Compound (A-6)) | PDB MMDB Reactome pathway KEGG UniProtKB/SwissProt B.MOAD DrugBank antibodypedia GoogleScholar AffyNet ![]() | PC cid PC sid UniChem | US Patent | n/a | n/a | 38.4 | n/a | n/a | n/a | n/a | n/a | n/a |
Dana-Farber Cancer Institute, Inc. US Patent | Assay Description The in vitro activity of the compounds described herein in inhibiting TAK1, HCK and other kinases were obtained using an Invitrogen Select Screening ... | US Patent US10633348 (2020) BindingDB Entry DOI: 10.7270/Q22Z18JR | |||||||||||
More data for this Ligand-Target Pair | |||||||||||||
Nuclear receptor subfamily 2 group C member 2 (Homo sapiens (Human)) | BDBM439303![]() (US10633348, Compound (A-17)) | PDB MMDB Reactome pathway KEGG UniProtKB/SwissProt B.MOAD antibodypedia GoogleScholar AffyNet ![]() | PC cid PC sid UniChem | US Patent | n/a | n/a | 45 | n/a | n/a | n/a | n/a | n/a | n/a |
Dana-Farber Cancer Institute, Inc. US Patent | Assay Description The in vitro activity of the compounds described herein in inhibiting TAK1, HCK and other kinases were obtained using an Invitrogen Select Screening ... | US Patent US10633348 (2020) BindingDB Entry DOI: 10.7270/Q22Z18JR | |||||||||||
More data for this Ligand-Target Pair | |||||||||||||
Nuclear receptor subfamily 2 group C member 2 (Homo sapiens (Human)) | BDBM439318![]() (US10633348, Compound (A-14)) | PDB MMDB Reactome pathway KEGG UniProtKB/SwissProt B.MOAD antibodypedia GoogleScholar AffyNet ![]() | PC cid PC sid UniChem | US Patent | n/a | n/a | 53.8 | n/a | n/a | n/a | n/a | n/a | n/a |
Dana-Farber Cancer Institute, Inc. US Patent | Assay Description The in vitro activity of the compounds described herein in inhibiting TAK1, HCK and other kinases were obtained using an Invitrogen Select Screening ... | US Patent US10633348 (2020) BindingDB Entry DOI: 10.7270/Q22Z18JR | |||||||||||
More data for this Ligand-Target Pair | |||||||||||||
Tyrosine-protein kinase HCK (Homo sapiens (Human)) | BDBM439307![]() (US10633348, Compound (A-5)) | PDB MMDB Reactome pathway KEGG UniProtKB/SwissProt B.MOAD DrugBank antibodypedia GoogleScholar AffyNet ![]() | PC cid PC sid UniChem | US Patent | n/a | n/a | 61.8 | n/a | n/a | n/a | n/a | n/a | n/a |
Dana-Farber Cancer Institute, Inc. US Patent | Assay Description The in vitro activity of the compounds described herein in inhibiting TAK1, HCK and other kinases were obtained using an Invitrogen Select Screening ... | US Patent US10633348 (2020) BindingDB Entry DOI: 10.7270/Q22Z18JR | |||||||||||
More data for this Ligand-Target Pair | |||||||||||||
Nuclear receptor subfamily 2 group C member 2 (Homo sapiens (Human)) | BDBM439308![]() (US10633348, Compound (A-6)) | PDB MMDB Reactome pathway KEGG UniProtKB/SwissProt B.MOAD antibodypedia GoogleScholar AffyNet ![]() | PC cid PC sid UniChem | US Patent | n/a | n/a | 63.5 | n/a | n/a | n/a | n/a | n/a | n/a |
Dana-Farber Cancer Institute, Inc. US Patent | Assay Description The in vitro activity of the compounds described herein in inhibiting TAK1, HCK and other kinases were obtained using an Invitrogen Select Screening ... | US Patent US10633348 (2020) BindingDB Entry DOI: 10.7270/Q22Z18JR | |||||||||||
More data for this Ligand-Target Pair | |||||||||||||
Nuclear receptor subfamily 2 group C member 2 (Homo sapiens (Human)) | BDBM439309![]() (US10633348, Compound (A-7)) | PDB MMDB Reactome pathway KEGG UniProtKB/SwissProt B.MOAD antibodypedia GoogleScholar AffyNet ![]() | PC cid PC sid UniChem | US Patent | n/a | n/a | 71.7 | n/a | n/a | n/a | n/a | n/a | n/a |
Dana-Farber Cancer Institute, Inc. US Patent | Assay Description The in vitro activity of the compounds described herein in inhibiting TAK1, HCK and other kinases were obtained using an Invitrogen Select Screening ... | US Patent US10633348 (2020) BindingDB Entry DOI: 10.7270/Q22Z18JR | |||||||||||
More data for this Ligand-Target Pair | |||||||||||||
Nuclear receptor subfamily 2 group C member 2 (Homo sapiens (Human)) | BDBM439316![]() (US10633348, Compound (A-12)) | PDB MMDB Reactome pathway KEGG UniProtKB/SwissProt B.MOAD antibodypedia GoogleScholar AffyNet ![]() | PC cid PC sid UniChem | US Patent | n/a | n/a | 76.2 | n/a | n/a | n/a | n/a | n/a | n/a |
Dana-Farber Cancer Institute, Inc. US Patent | Assay Description The in vitro activity of the compounds described herein in inhibiting TAK1, HCK and other kinases were obtained using an Invitrogen Select Screening ... | US Patent US10633348 (2020) BindingDB Entry DOI: 10.7270/Q22Z18JR | |||||||||||
More data for this Ligand-Target Pair | |||||||||||||
Nuclear receptor subfamily 2 group C member 2 (Homo sapiens (Human)) | BDBM439305![]() (US10633348, Compound (A-3)) | PDB MMDB Reactome pathway KEGG UniProtKB/SwissProt B.MOAD antibodypedia GoogleScholar AffyNet ![]() | PC cid PC sid UniChem | US Patent | n/a | n/a | 92 | n/a | n/a | n/a | n/a | n/a | n/a |
Dana-Farber Cancer Institute, Inc. US Patent | Assay Description The in vitro activity of the compounds described herein in inhibiting TAK1, HCK and other kinases were obtained using an Invitrogen Select Screening ... | US Patent US10633348 (2020) BindingDB Entry DOI: 10.7270/Q22Z18JR | |||||||||||
More data for this Ligand-Target Pair | |||||||||||||
Nuclear receptor subfamily 2 group C member 2 (Homo sapiens (Human)) | BDBM439304![]() (US10633348, Compound (A-2)) | PDB MMDB Reactome pathway KEGG UniProtKB/SwissProt B.MOAD antibodypedia GoogleScholar AffyNet ![]() | PC cid PC sid UniChem | US Patent | n/a | n/a | 100 | n/a | n/a | n/a | n/a | n/a | n/a |
Dana-Farber Cancer Institute, Inc. US Patent | Assay Description The in vitro activity of the compounds described herein in inhibiting TAK1, HCK and other kinases were obtained using an Invitrogen Select Screening ... | US Patent US10633348 (2020) BindingDB Entry DOI: 10.7270/Q22Z18JR | |||||||||||
More data for this Ligand-Target Pair | |||||||||||||
Nuclear receptor subfamily 2 group C member 2 (Homo sapiens (Human)) | BDBM439307![]() (US10633348, Compound (A-5)) | PDB MMDB Reactome pathway KEGG UniProtKB/SwissProt B.MOAD antibodypedia GoogleScholar AffyNet ![]() | PC cid PC sid UniChem | US Patent | n/a | n/a | 100 | n/a | n/a | n/a | n/a | n/a | n/a |
Dana-Farber Cancer Institute, Inc. US Patent | Assay Description The in vitro activity of the compounds described herein in inhibiting TAK1, HCK and other kinases were obtained using an Invitrogen Select Screening ... | US Patent US10633348 (2020) BindingDB Entry DOI: 10.7270/Q22Z18JR | |||||||||||
More data for this Ligand-Target Pair | |||||||||||||
Tyrosine-protein kinase HCK (Homo sapiens (Human)) | BDBM439319![]() (US10633348, Compound (A-15)) | PDB MMDB Reactome pathway KEGG UniProtKB/SwissProt B.MOAD DrugBank antibodypedia GoogleScholar AffyNet ![]() | PC cid PC sid UniChem | US Patent | n/a | n/a | 116 | n/a | n/a | n/a | n/a | n/a | n/a |
Dana-Farber Cancer Institute, Inc. US Patent | Assay Description The in vitro activity of the compounds described herein in inhibiting TAK1, HCK and other kinases were obtained using an Invitrogen Select Screening ... | US Patent US10633348 (2020) BindingDB Entry DOI: 10.7270/Q22Z18JR | |||||||||||
More data for this Ligand-Target Pair | |||||||||||||
Nuclear receptor subfamily 2 group C member 2 (Homo sapiens (Human)) | BDBM439319![]() (US10633348, Compound (A-15)) | PDB MMDB Reactome pathway KEGG UniProtKB/SwissProt B.MOAD antibodypedia GoogleScholar AffyNet ![]() | PC cid PC sid UniChem | US Patent | n/a | n/a | 136 | n/a | n/a | n/a | n/a | n/a | n/a |
Dana-Farber Cancer Institute, Inc. US Patent | Assay Description The in vitro activity of the compounds described herein in inhibiting TAK1, HCK and other kinases were obtained using an Invitrogen Select Screening ... | US Patent US10633348 (2020) BindingDB Entry DOI: 10.7270/Q22Z18JR | |||||||||||
More data for this Ligand-Target Pair | |||||||||||||
Tyrosine-protein kinase HCK (Homo sapiens (Human)) | BDBM439305![]() (US10633348, Compound (A-3)) | PDB MMDB Reactome pathway KEGG UniProtKB/SwissProt B.MOAD DrugBank antibodypedia GoogleScholar AffyNet ![]() | PC cid PC sid UniChem | US Patent | n/a | n/a | 185 | n/a | n/a | n/a | n/a | n/a | n/a |
Dana-Farber Cancer Institute, Inc. US Patent | Assay Description The in vitro activity of the compounds described herein in inhibiting TAK1, HCK and other kinases were obtained using an Invitrogen Select Screening ... | US Patent US10633348 (2020) BindingDB Entry DOI: 10.7270/Q22Z18JR | |||||||||||
More data for this Ligand-Target Pair | |||||||||||||
Tyrosine-protein kinase HCK (Homo sapiens (Human)) | BDBM439304![]() (US10633348, Compound (A-2)) | PDB MMDB Reactome pathway KEGG UniProtKB/SwissProt B.MOAD DrugBank antibodypedia GoogleScholar AffyNet ![]() | PC cid PC sid UniChem | US Patent | n/a | n/a | 253 | n/a | n/a | n/a | n/a | n/a | n/a |
Dana-Farber Cancer Institute, Inc. US Patent | Assay Description The in vitro activity of the compounds described herein in inhibiting TAK1, HCK and other kinases were obtained using an Invitrogen Select Screening ... | US Patent US10633348 (2020) BindingDB Entry DOI: 10.7270/Q22Z18JR | |||||||||||
More data for this Ligand-Target Pair | |||||||||||||
Tyrosine-protein kinase HCK (Homo sapiens (Human)) | BDBM438001![]() (US10633348, Compound (A-1) | US10633348, Compound ...) | PDB MMDB Reactome pathway KEGG UniProtKB/SwissProt B.MOAD DrugBank antibodypedia GoogleScholar AffyNet ![]() | PC cid PC sid UniChem | US Patent | n/a | n/a | 275 | n/a | n/a | n/a | n/a | n/a | n/a |
Dana-Farber Cancer Institute, Inc. US Patent | Assay Description The in vitro activity of the compounds described herein in inhibiting TAK1, HCK and other kinases were obtained using an Invitrogen Select Screening ... | US Patent US10633348 (2020) BindingDB Entry DOI: 10.7270/Q22Z18JR | |||||||||||
More data for this Ligand-Target Pair | |||||||||||||
Nuclear receptor subfamily 2 group C member 2 (Homo sapiens (Human)) | BDBM438001![]() (US10633348, Compound (A-1) | US10633348, Compound ...) | PDB MMDB Reactome pathway KEGG UniProtKB/SwissProt B.MOAD antibodypedia GoogleScholar AffyNet ![]() | PC cid PC sid UniChem | US Patent | n/a | n/a | 364 | n/a | n/a | n/a | n/a | n/a | n/a |
Dana-Farber Cancer Institute, Inc. US Patent | Assay Description The in vitro activity of the compounds described herein in inhibiting TAK1, HCK and other kinases were obtained using an Invitrogen Select Screening ... | US Patent US10633348 (2020) BindingDB Entry DOI: 10.7270/Q22Z18JR | |||||||||||
More data for this Ligand-Target Pair | |||||||||||||
Tyrosine-protein kinase HCK (Homo sapiens (Human)) | BDBM439306![]() (US10633348, Compound (A-4)) | PDB MMDB Reactome pathway KEGG UniProtKB/SwissProt B.MOAD DrugBank antibodypedia GoogleScholar AffyNet ![]() | PC cid PC sid UniChem | US Patent | n/a | n/a | 382 | n/a | n/a | n/a | n/a | n/a | n/a |
Dana-Farber Cancer Institute, Inc. US Patent | Assay Description The in vitro activity of the compounds described herein in inhibiting TAK1, HCK and other kinases were obtained using an Invitrogen Select Screening ... | US Patent US10633348 (2020) BindingDB Entry DOI: 10.7270/Q22Z18JR | |||||||||||
More data for this Ligand-Target Pair | |||||||||||||
Tyrosine-protein kinase HCK (Homo sapiens (Human)) | BDBM439317![]() (US10633348, Compound (A-13)) | PDB MMDB Reactome pathway KEGG UniProtKB/SwissProt B.MOAD DrugBank antibodypedia GoogleScholar AffyNet ![]() | PC cid PC sid UniChem | US Patent | n/a | n/a | 392 | n/a | n/a | n/a | n/a | n/a | n/a |
Dana-Farber Cancer Institute, Inc. US Patent | Assay Description The in vitro activity of the compounds described herein in inhibiting TAK1, HCK and other kinases were obtained using an Invitrogen Select Screening ... | US Patent US10633348 (2020) BindingDB Entry DOI: 10.7270/Q22Z18JR | |||||||||||
More data for this Ligand-Target Pair | |||||||||||||
Nuclear receptor subfamily 2 group C member 2 (Homo sapiens (Human)) | BDBM439317![]() (US10633348, Compound (A-13)) | PDB MMDB Reactome pathway KEGG UniProtKB/SwissProt B.MOAD antibodypedia GoogleScholar AffyNet ![]() | PC cid PC sid UniChem | US Patent | n/a | n/a | 400 | n/a | n/a | n/a | n/a | n/a | n/a |
Dana-Farber Cancer Institute, Inc. US Patent | Assay Description The in vitro activity of the compounds described herein in inhibiting TAK1, HCK and other kinases were obtained using an Invitrogen Select Screening ... | US Patent US10633348 (2020) BindingDB Entry DOI: 10.7270/Q22Z18JR | |||||||||||
More data for this Ligand-Target Pair | |||||||||||||
Nuclear receptor subfamily 2 group C member 2 (Homo sapiens (Human)) | BDBM438001![]() (US10633348, Compound (A-1) | US10633348, Compound ...) | PDB MMDB Reactome pathway KEGG UniProtKB/SwissProt B.MOAD antibodypedia GoogleScholar AffyNet ![]() | PC cid PC sid UniChem | US Patent | n/a | n/a | 487 | n/a | n/a | n/a | n/a | n/a | n/a |
Dana-Farber Cancer Institute, Inc. US Patent | Assay Description The in vitro activity of the compounds described herein in inhibiting TAK1, HCK and other kinases were obtained using an Invitrogen Select Screening ... | US Patent US10633348 (2020) BindingDB Entry DOI: 10.7270/Q22Z18JR | |||||||||||
More data for this Ligand-Target Pair | |||||||||||||
Nuclear receptor subfamily 2 group C member 2 (Homo sapiens (Human)) | BDBM439306![]() (US10633348, Compound (A-4)) | PDB MMDB Reactome pathway KEGG UniProtKB/SwissProt B.MOAD antibodypedia GoogleScholar AffyNet ![]() | PC cid PC sid UniChem | US Patent | n/a | n/a | 591 | n/a | n/a | n/a | n/a | n/a | n/a |
Dana-Farber Cancer Institute, Inc. US Patent | Assay Description The in vitro activity of the compounds described herein in inhibiting TAK1, HCK and other kinases were obtained using an Invitrogen Select Screening ... | US Patent US10633348 (2020) BindingDB Entry DOI: 10.7270/Q22Z18JR | |||||||||||
More data for this Ligand-Target Pair | |||||||||||||
Tyrosine-protein kinase HCK (Homo sapiens (Human)) | BDBM438001![]() (US10633348, Compound (A-1) | US10633348, Compound ...) | PDB MMDB Reactome pathway KEGG UniProtKB/SwissProt B.MOAD DrugBank antibodypedia GoogleScholar AffyNet ![]() | PC cid PC sid UniChem | US Patent | n/a | n/a | 889 | n/a | n/a | n/a | n/a | n/a | n/a |
Dana-Farber Cancer Institute, Inc. US Patent | Assay Description The in vitro activity of the compounds described herein in inhibiting TAK1, HCK and other kinases were obtained using an Invitrogen Select Screening ... | US Patent US10633348 (2020) BindingDB Entry DOI: 10.7270/Q22Z18JR | |||||||||||
More data for this Ligand-Target Pair | |||||||||||||
Nuclear receptor subfamily 2 group C member 2 (Homo sapiens (Human)) | BDBM439314![]() (US10633348, Compound (A-18)) | PDB MMDB Reactome pathway KEGG UniProtKB/SwissProt B.MOAD antibodypedia GoogleScholar AffyNet ![]() | PC cid PC sid UniChem | US Patent | n/a | n/a | 1.75E+3 | n/a | n/a | n/a | n/a | n/a | n/a |
Dana-Farber Cancer Institute, Inc. US Patent | Assay Description The in vitro activity of the compounds described herein in inhibiting TAK1, HCK and other kinases were obtained using an Invitrogen Select Screening ... | US Patent US10633348 (2020) BindingDB Entry DOI: 10.7270/Q22Z18JR | |||||||||||
More data for this Ligand-Target Pair | |||||||||||||
Tyrosine-protein kinase BTK (Homo sapiens (Human)) | BDBM439303![]() (US10633348, Compound (A-17)) | PDB MMDB NCI pathway Reactome pathway KEGG UniProtKB/SwissProt B.MOAD DrugBank antibodypedia GoogleScholar AffyNet ![]() | PC cid PC sid UniChem | US Patent | n/a | n/a | 3.38E+3 | n/a | n/a | n/a | n/a | n/a | n/a |
Dana-Farber Cancer Institute, Inc. US Patent | Assay Description The in vitro activity of the compounds described herein in inhibiting TAK1, HCK and other kinases were obtained using an Invitrogen Select Screening ... | US Patent US10633348 (2020) BindingDB Entry DOI: 10.7270/Q22Z18JR | |||||||||||
More data for this Ligand-Target Pair | |||||||||||||
Tyrosine-protein kinase HCK (Homo sapiens (Human)) | BDBM439314![]() (US10633348, Compound (A-18)) | PDB MMDB Reactome pathway KEGG UniProtKB/SwissProt B.MOAD DrugBank antibodypedia GoogleScholar AffyNet ![]() | PC cid PC sid UniChem | US Patent | n/a | n/a | 6.98E+3 | n/a | n/a | n/a | n/a | n/a | n/a |
Dana-Farber Cancer Institute, Inc. US Patent | Assay Description The in vitro activity of the compounds described herein in inhibiting TAK1, HCK and other kinases were obtained using an Invitrogen Select Screening ... | US Patent US10633348 (2020) BindingDB Entry DOI: 10.7270/Q22Z18JR | |||||||||||
More data for this Ligand-Target Pair | |||||||||||||
Nuclear receptor subfamily 2 group C member 2 (Homo sapiens (Human)) | BDBM439312![]() (US10633348, Compound (A-9)) | PDB MMDB Reactome pathway KEGG UniProtKB/SwissProt B.MOAD antibodypedia GoogleScholar AffyNet ![]() | PC cid PC sid UniChem | US Patent | n/a | n/a | 7.31E+3 | n/a | n/a | n/a | n/a | n/a | n/a |
Dana-Farber Cancer Institute, Inc. US Patent | Assay Description The in vitro activity of the compounds described herein in inhibiting TAK1, HCK and other kinases were obtained using an Invitrogen Select Screening ... | US Patent US10633348 (2020) BindingDB Entry DOI: 10.7270/Q22Z18JR | |||||||||||
More data for this Ligand-Target Pair | |||||||||||||
Tyrosine-protein kinase HCK (Homo sapiens (Human)) | BDBM439312![]() (US10633348, Compound (A-9)) | PDB MMDB Reactome pathway KEGG UniProtKB/SwissProt B.MOAD DrugBank antibodypedia GoogleScholar AffyNet ![]() | PC cid PC sid UniChem | US Patent | n/a | n/a | >1.00E+4 | n/a | n/a | n/a | n/a | n/a | n/a |
Dana-Farber Cancer Institute, Inc. US Patent | Assay Description The in vitro activity of the compounds described herein in inhibiting TAK1, HCK and other kinases were obtained using an Invitrogen Select Screening ... | US Patent US10633348 (2020) BindingDB Entry DOI: 10.7270/Q22Z18JR | |||||||||||
More data for this Ligand-Target Pair | |||||||||||||
Tyrosine-protein kinase BTK (Homo sapiens (Human)) | BDBM439307![]() (US10633348, Compound (A-5)) | PDB MMDB NCI pathway Reactome pathway KEGG UniProtKB/SwissProt B.MOAD DrugBank antibodypedia GoogleScholar AffyNet ![]() | PC cid PC sid UniChem | US Patent | n/a | n/a | >1.00E+4 | n/a | n/a | n/a | n/a | n/a | n/a |
Dana-Farber Cancer Institute, Inc. US Patent | Assay Description The in vitro activity of the compounds described herein in inhibiting TAK1, HCK and other kinases were obtained using an Invitrogen Select Screening ... | US Patent US10633348 (2020) BindingDB Entry DOI: 10.7270/Q22Z18JR | |||||||||||
More data for this Ligand-Target Pair | |||||||||||||
Nuclear receptor subfamily 2 group C member 2 (Homo sapiens (Human)) | BDBM439313![]() (US10633348, Compound (A-10)) | PDB MMDB Reactome pathway KEGG UniProtKB/SwissProt B.MOAD antibodypedia GoogleScholar AffyNet ![]() | PC cid PC sid UniChem | US Patent | n/a | n/a | >1.00E+4 | n/a | n/a | n/a | n/a | n/a | n/a |
Dana-Farber Cancer Institute, Inc. US Patent | Assay Description The in vitro activity of the compounds described herein in inhibiting TAK1, HCK and other kinases were obtained using an Invitrogen Select Screening ... | US Patent US10633348 (2020) BindingDB Entry DOI: 10.7270/Q22Z18JR | |||||||||||
More data for this Ligand-Target Pair | |||||||||||||
Nuclear receptor subfamily 2 group C member 2 (Homo sapiens (Human)) | BDBM439315![]() (US10633348, Compound (A-11)) | PDB MMDB Reactome pathway KEGG UniProtKB/SwissProt B.MOAD antibodypedia GoogleScholar AffyNet ![]() | PC cid PC sid UniChem | US Patent | n/a | n/a | >1.00E+4 | n/a | n/a | n/a | n/a | n/a | n/a |
Dana-Farber Cancer Institute, Inc. US Patent | Assay Description The in vitro activity of the compounds described herein in inhibiting TAK1, HCK and other kinases were obtained using an Invitrogen Select Screening ... | US Patent US10633348 (2020) BindingDB Entry DOI: 10.7270/Q22Z18JR | |||||||||||
More data for this Ligand-Target Pair | |||||||||||||
Tyrosine-protein kinase HCK (Homo sapiens (Human)) | BDBM439315![]() (US10633348, Compound (A-11)) | PDB MMDB Reactome pathway KEGG UniProtKB/SwissProt B.MOAD DrugBank antibodypedia GoogleScholar AffyNet ![]() | PC cid PC sid UniChem | US Patent | n/a | n/a | >1.00E+4 | n/a | n/a | n/a | n/a | n/a | n/a |
Dana-Farber Cancer Institute, Inc. US Patent | Assay Description The in vitro activity of the compounds described herein in inhibiting TAK1, HCK and other kinases were obtained using an Invitrogen Select Screening ... | US Patent US10633348 (2020) BindingDB Entry DOI: 10.7270/Q22Z18JR | |||||||||||
More data for this Ligand-Target Pair | |||||||||||||
Tyrosine-protein kinase HCK (Homo sapiens (Human)) | BDBM439313![]() (US10633348, Compound (A-10)) | PDB MMDB Reactome pathway KEGG UniProtKB/SwissProt B.MOAD DrugBank antibodypedia GoogleScholar AffyNet ![]() | PC cid PC sid UniChem | US Patent | n/a | n/a | >1.00E+4 | n/a | n/a | n/a | n/a | n/a | n/a |
Dana-Farber Cancer Institute, Inc. US Patent | Assay Description The in vitro activity of the compounds described herein in inhibiting TAK1, HCK and other kinases were obtained using an Invitrogen Select Screening ... | US Patent US10633348 (2020) BindingDB Entry DOI: 10.7270/Q22Z18JR | |||||||||||
More data for this Ligand-Target Pair |